生物类似药后缀标识在上市后不良事件报告中的使用分析

作者：Danijela Stojanovic、Lisa Wolf、M. Stacey Ricci、Monica A. Muñoz

单位：Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.；Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.